PPBT news & sentiment — PURPLE BIOTECH LTD.

APR 23·Stock TitanMed

Doctors tied to approved cancer immune therapies join Purple board

Purple Biotech (NASDAQ: PPBT) has established a Scientific Advisory Board (SAB) for its CAPTN-3 tri-specific antibody platform to guide its progression toward clinical-stage immunotherapy. The SAB includes experts in NK and T-cell biology and those with direct experience in developing approved T-cell engager therapies. This board will provide strategic guidance on translational science, NK and T cell biology, and clinical strategy as the company prepares for first-in-human studies.

MAR 31·Stock Titan

Purple Biotech (PPBT) CFO details multi-million share options and RSUs

Purple Biotech's CFO, Shai S. Lankry, has updated his equity holdings, revealing significant stock options and restricted stock units (RSUs). The filing shows options to purchase a total of 6,550,000 ordinary shares under the company's 2016 Equity-Based Incentive Plan, with varying exercise prices and expiration dates in 2030. Additionally, Lankry holds 3,254,167 unvested RSUs, which will be settled in ordinary shares based on time-based vesting conditions.

MAR 31·Stock Titan

Purple Biotech (PPBT) executive reports 9.25M shares plus multi-year options

Michael Schickler, Head of Clinical & Reg Affairs at Purple Biotech (PPBT), has filed an initial ownership report detailing his holdings. The report indicates beneficial ownership of 9,254,472 Ordinary Shares, which include 6,958,334 unvested restricted stock units (RSUs). Schickler also holds several stock options with varying exercise prices and expiration dates, ranging from April 2027 to October 2030, some of which are fully vested while others vest in quarterly installments.

$PPBT

Doctors tied to approved cancer immune therapies join Purple board

Purple Biotech (PPBT) CFO details multi-million share options and RSUs

Purple Biotech (PPBT) executive reports 9.25M shares plus multi-year options

News on $PPBT